Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19x22 CAR T in Pediatric R/R B-ALL
NCT06559189Phase 1Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Sep 2024
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD19/CD22 CAR-T in B cell acute lymphoblastic leukemia (B-ALL), sponsored by University of Colorado Denver. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Sep 2024; status: recruiting.
02
Drugs
CD19/CD22 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06559189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06559189.